Not finding it? Sign in to also search OpenAlex live.
-
MPN with multiple driver clones show distinct patterns of therapy response and progression - “MPN double driver”2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Kirsi Marjaana Manz, Tina M. Schnoeder, Francesca Palandri, Filippo Branzanti, Heike Luise Pahl, Martin Grießhammer, +20 more
3citations -
Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer: An update on recurrence-free survival and correlative biomarkers.2024 Journal of Clinical Oncology conference-abstract Medicine Endometrial and Cervical Cancer Treatments
Marco de Bruyn, Anneke L. Eerkens, Koen Brummel, Annegé Vledder, Sterre T. Paijens, Marta Requesens, +14 more
1citations -
Abstract 5051: Evolutionary characterization and refinement of copy-number high endometrial carcinoma2024 Cancer Research conference-abstract Biochemistry, Genetics and Molecular Biology Cancer Genomics and Diagnostics
Claire J.H. Kramer, Dina Ruano, Aliah Hawari, Félix Blanc‐Durand, Cor Doede de Kroon, Judith R. Kroep, +9 more
0citations -
Long-term outcome and risk factors for relapse after allogeneic hematopoietic stem cell transplantation in myelofibrosis: Results from a large multicenter cohort2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Julia-Annabell Georgi, Sebastian Stasik, Michael Krämer, Tobias A.W. Holderried, Jochen J. Frietsch, Stefan Klein, +18 more
1citations -
Abstract 794: Molecular analysis of archival inflammatory myofibroblastic tumor tissue samples from EORTC 90101 “CREATE” and correlation with response to crizotinib2020 Cancer Research conference-abstract Medicine IgG4-Related and Inflammatory Diseases Open access
Che‐Jui Lee, Patrick Schöffski, Elodie Modave, Bram Boeckx, Diether Lambrechts, Maria Dêbiec‐Rychter, +5 more
0citations -
MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +9 more
2citations -
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi)
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +9 more
1citations -
Fedratinib in combination with CC-486, an oral hypomethylating agent, in patients with accelerated phase myelofibrosis: Results from the phase I/II famy trial2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Nadja Jaekel, Susann Schulze, Christina Zahn, Andreas Wienke, Michael Richter, Steffen Koschmieder, +5 more
1citations -
Abstract CT021: Preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients (pts) with stage IV NSCLC2024 Cancer Research conference-abstract Immunology and Microbiology Immunotherapy and Immune Responses
Willemijn S.M.E. Theelen, Maurice Pérol, Kristof Cuppens, Ingel Demedts, Frank Borm, Bonne Biesma, +17 more
3citations -
Ropeginterferon alfa-2b in essential thrombocythemia of all risk levels ineligible for standard cytoreduction: 12-month primary endpoint analysis from the ROP-ET phase 3 study2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Jean‐Jacques Kiladjian, Francesca Palandri, Eloise Beggiato, Alberto Álvarez‐Larrán, Konstanze Döhner, Veronika Buxhofer‐Ausch
2citations